← Therapy pipeline
Investigational · Obesity development

Berobenatide

PF-08653944 · PF’3944 · MET-097i · Pfizer

Long-acting injectable GLP-1 agonist testing weekly and monthly schedules.

GLP-1
Other study areas
Type 2 diabetesWeight maintenance / switchingSleep apneaKnee osteoarthritisStress urinary incontinence
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 9, 2026
SponsorPfizer
TargetsGLP-1
RouteInjection
DevelopmentFormulations differ
01 / Evidence

Selected study results

VESPER-3Placebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −12.3 percentage points · 28 weeks · Phase 2b
Phase 2b · Injection · Sponsor-reported numerical results

Placebo-adjusted weight-loss difference · 28 weeks

Study focus: Weight management without type 2 diabetes

Placebo-adjusted difference, not the total change in the active arm.

Weekly-to-monthly dosing maintained weight reduction through week 28.

Difference versus placebo
12.3 percentage points

Adults with obesity/overweight without diabetes; approximately 54 per arm across five arms · Weekly escalation to 1.2 mg, then 4.8 mg monthly (Arm 3) · N not included in this summary · Efficacy estimand; sponsor topline. Results & methods ↗

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3VESPER obesity studies initiated
InjectionOnce monthly maintenance
Phase 3VESPER-6 initiated
Milestone → next

Latest: Phase 3 VESPER studies include separate monthly VESPER-OA 1 and weekly VESPER-OA-2 knee-osteoarthritis protocols. Both are recruiting; planned enrollment is not efficacy evidence.

Next: Phase 3 obesity readouts and monthly maintenance results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies5 records

Phase 3

VESPER-4

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Once-weekly berobenatide in adults with obesity or overweight without type 2 diabetes.

Phase 3

VESPER-5

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Once-weekly berobenatide in adults with obesity or overweight and type 2 diabetes.

Phase 3

VESPER-6

Weight management with monthly dosing
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Once-monthly berobenatide in adults with obesity or overweight.

Phase 3

VESPER-SWITCH

Weight maintenance / switching
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Phase 3 switching study in adults with obesity or overweight; registry recruiting.

Phase 3

VESPER-OA-2

Weight management with knee osteoarthritis
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

C6491023: weekly berobenatide versus placebo for 52 weeks; with or without type 2 diabetes. Planned enrollment 756; actual start October 26, 2026; recruiting. Separate from monthly VESPER-OA 1 (NCT07919678). No registry results posted.

Phase 2 studies3 records

Phase 2b

VESPER-3

Monthly dosing / maintenance
Study: OngoingResults: Sponsor results shown aboveStatus reviewed November 2026

Evaluated transition from weekly titration to monthly dosing in adults with obesity or overweight without type 2 diabetes; sponsor topline reported.

Related conditions and outcomes

Phase 3 studies4 records

Phase 3

VESPER-OSA-1

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Phase 3 obstructive-sleep-apnea study; registry recruiting.

Phase 3

VESPER-OSA-2

Sleep-apnea outcomes
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Separate Phase 3 obstructive-sleep-apnea study; registered, not yet recruiting.

Phase 3

VESPER-SUI

Stress urinary incontinence
Study: Not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Placebo-controlled trial in an estimated 900 adult women with stress urinary incontinence and BMI ≥27 kg/m². Change in stress incontinence episode frequency at week 52 is the primary endpoint. Body-weight change is secondary.

Phase 3

VESPER-OA 1

Knee osteoarthritis · monthly dosing
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

C6491022: monthly subcutaneous berobenatide versus placebo for 52 weeks in adults with BMI ≥27 and symptomatic radiographic knee osteoarthritis; diabetes excluded. Planned enrollment 656; actual start October 26, 2026; first posted November 5. WOMAC pain is the primary endpoint; weight is secondary. No results posted.